Kyle
Jenne rejoins company to lead commercial
strategy
Onaiza
Cadoret-Manier departing for new career opportunity
With broad commercial capabilities in place,
Ionis ready to execute on its first independent launches
CARLSBAD, Calif., Feb. 29,
2024 /PRNewswire/ -- Ionis Pharmaceuticals,
Inc. (Nasdaq: IONS) announced today that Kyle Jenne has
rejoined Ionis as executive vice president, chief global product
strategy officer, to lead all aspects of commercialization at the
Company. Mr. Jenne has more than 25 years of biopharmaceutical
commercial and executive leadership experience and has launched
innovative medicines across a broad range of therapeutic areas
including cardiovascular, neurology and allergy.
Onaiza Cadoret-Manier, chief
global product strategy and operations officer, is leaving the
company to pursue another opportunity. To support the transition,
Ms. Cadoret-Manier will remain in a full-time capacity through
March 15, after which she will serve
as an advisor for a period of time.
"I thank Onaiza for her tremendous vision and contributions in
establishing Ionis' foundational commercial organization and
capabilities over the last four years as Ionis evolved into a fully
integrated biopharmaceutical company. She has built a stellar team
of professionals with deep experience across all aspects of
commercialization," said Brett P.
Monia, Ionis' chief executive officer. "With these core
capabilities in place and our first co-commercialization underway
for WAINUA™ (eplontersen), we're excited to welcome Kyle back
to spearhead our commercial growth as we work to advance a steady
cadence of medicines starting with our first potential independent
U.S. launches for olezarsen in familial chylomicronemia syndrome
and donidalorsen in hereditary angioedema. Kyle's broad commercial
and launch experience, coupled with his strong existing
relationships at Ionis, will enable him to rapidly and seamlessly
add value to our commercial organization during this important time
for Ionis and the patients who are counting on us."
Mr. Jenne has broad experience in executive leadership
roles and expertise in launching and commercializing innovative
medicines in the U.S. and globally. He brings deep relevant
experience in a wide range of therapeutic areas. Mr.
Jenne previously spent five years in commercial leadership
roles at Ionis and Akcea, which was fully acquired by Ionis in
2020. His most recent role at Ionis was as EVP & chief
commercial officer. During his time at Ionis and Akcea, Mr.
Jenne built commercial capabilities in many of Ionis' key
disease areas including transthyretin-mediated amyloidosis and
familial chylomicronemia syndrome (FCS). He also played a key role
in establishing the co-commercialization collaboration with
AstraZeneca for WAINUA. Earlier in his career, Mr. Jenne held
commercial roles for companies including Schering Plough, King
Pharmaceuticals, Acorda Therapeutics and Praecis
Pharmaceuticals.
"As a fully integrated biopharma company, Ionis is demonstrating
its leadership with an innovative pipeline of wholly owned mid- and
late-stage investigational medicines, each of which has the
potential to meet important unmet needs for people with serious
diseases. I am committed to ensuring we fully realize the potential
of these innovative medicines to reach patients and their
healthcare providers, beginning with the anticipated upcoming
launches for olezarsen and donidalorsen," said Mr. Jenne. "On
a personal level, I'm thrilled to be back at Ionis working with
this incredibly talented and dedicated team."
About Ionis Pharmaceuticals,
Inc.
For three decades, Ionis has invented medicines that bring
better futures to people with serious diseases. Ionis currently has
five marketed medicines and a leading pipeline in neurology,
cardiology, and other areas of high patient need. As the pioneer in
RNA-targeted medicines, Ionis continues to drive innovation in RNA
therapies in addition to advancing new approaches in gene editing.
A deep understanding of disease biology and industry-leading
technology propels our work, coupled with a passion and urgency to
deliver life-changing advances for patients. To learn more
about Ionis, visit Ionispharma.com and follow us on X (Twitter) and
LinkedIn.
Forward-looking
Statements
This press release includes forward-looking statements regarding
Ionis' business, and the therapeutic and commercial potential of
Ionis' commercial medicines, additional medicines in development
and technologies. Any statement describing Ionis' goals,
expectations, financial or other projections, intentions, or
beliefs is a forward-looking statement and should be considered an
at-risk statement. Such statements are subject to certain risks and
uncertainties, including but not limited to those related to our
commercial products and the medicines in our pipeline, and
particularly those inherent in the process of discovering,
developing and commercializing medicines that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such medicines. Ionis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Ionis. Except as required by
law, we undertake no obligation to update any forward-looking
statements for any reason. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Ionis' programs are described in additional detail in
Ionis' annual report on Form 10-K for the year ended Dec. 31,
2023, and most recent Form 10-Q, which are on file with
the SEC. Copies of these and other documents are available
at www.ionispharma.com.
Ionis Pharmaceuticals® is a registered trademark of Ionis
Pharmaceuticals, Inc. WAINUA™ is a trademark of AstraZeneca
plc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-announces-new-chief-global-product-strategy-officer-to-lead-next-phase-of-commercial-growth-302074967.html
SOURCE Ionis Pharmaceuticals, Inc.